Osteoporosis,Fracture
Conditions
Interventions
Osteoporotic Fracture Group/Non-Fracture Control Group:N/A
Sponsors
The first affiliated hospital of guangzhou university of Chinese medicine
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Prospective Cohort Study Integrating Disease and Syndrome Differentiations for Osteoporosis: (1) Residency in urban or rural areas for >5 years; (2) Females aged 45 to = 18 years; (3) Receiving routine perioperative management and treatment for fractures at the participating hospitals; (4) Possessing sound cognitive ability to cooperate smoothly with surveys and examinations, and able to attend scheduled follow-ups; having provided written informed consent signed by the patient themselves and/or their legal guardian/family member.
Exclusion criteria
Exclusion criteria: 1. Prospective Cohort Study Integrating Disease and Syndrome Differentiations for Osteoporosis: (1) Individuals with psychiatric disorders who are unable to cooperate with the study assessments; (2) Individuals who are unwilling to participate or refuse to sign the informed consent form. 2. Prospective Multicenter Cohort Study on Osteoporotic Fractures: (1) Patients diagnosed with fractures of the small joints of the hands or feet, or skull fractures, by orthopedic specialists according to the ICD-10 diagnostic criteria; (2) Patients suffering fractures due to severe accidental injuries (including but not limited to physical assaults) or intentional self-harm (e.g., jumping from heights), as documented in admission records; (3) Patients with unstable vital signs, impaired consciousness (Montreal Cognitive Assessment [MoCA] score <12), or unmanageable severe pain rendering them unable to cooperate; (4) Patients with secondary osteoporosis caused by conditions such as osteomalacia, gout, or multiple myeloma; or those with severe comorbid endocrine disorders (e.g., Cushing's disease, hypercalcemia, hypercalciuria, or cardiac/renal dysfunction); (5) Patients taking other medications known to affect bone metabolism concurrently, which cannot be discontinued immediately; (6) Patients in advanced stages of deformity, disability, or loss of labor capacity; (7) Lactating or pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lumbar Spine BMD; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-Year All-Cause Mortality;Recurrent Fragility Fracture Incidence; | — |
Countries
China
Contacts
Public ContactYirong Zeng
The first affiliated hospital of guangzhou university of Chinese medicine
Outcome results
None listed